StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Other Respiratory & Immunology medicines by Quarter

Other Respiratory & Immunology medicines — Europe product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Other Respiratory & Immunology medicines: $33M in Q2 2026, up 120.0% from a year earlier.

Latest, Q2 2026
33
Period ended Jun 30, 2026
Change on a year earlier
+120.0%
15 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Other R&I | 69 | | 13 | | 9 | | 7 | | ( 55 ) | | 27 | | ( 1 ) | | ( 8 ) | | 33 | | n/m | | n/m | | 2 | | 6 | | 5”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Respiratory & Immunology medicines — Europe product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202633+120.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202624+84.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025150.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202515+15.4%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025150.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202513-7.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202415+114.3%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202413+85.7%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202415+114.3%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202414+75.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20237-12.5%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20237-12.5%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20237-22.2%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20238-52.9%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20228-85.5%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20228-81.0%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up other Respiratory & Immunology medicines

Cite this data

StockData. (2026). AstraZeneca Other Respiratory & Immunology medicines ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-ri-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.